Experience

Novavax

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President Clinical Research

  • Jul 2020 - Present

  Thrilled to have the opportunity to contribute to the fight against this pandemic and to join the team at Novavax! Thrilled to have the opportunity to contribute to the fight against this pandemic and to join the team at Novavax!



Lisa M Dunkle, MD Consultant

• New Haven area, Connecticut

• Independent Consultant

  • Jan 2020 - Jul 2020

  Experienced clinician and infectious diseases specialist with 30+ year career in clinical drug development and global regulatory submissions; expertise in small molecules and vaccines. Experienced clinician and infectious diseases specialist with 30+ year career in clinical drug development and global regulatory submissions; expertise in small molecules and vaccines.



Protein Sciences, a Sanofi Company

• Meriden, CT

• Clinical Program Team Leader - Respiratory

  • Jan 2018 - Jan 2020

  Responsible for clinical development of Flublok, Flublok in China and EU and oversight of RSV vaccine clinical development Responsible for clinical development of Flublok, Flublok in China and EU and oversight of RSV vaccine clinical development



Protein Sciences Corporation

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Medical Officer: head of clinical development

  • 2011 - Jan 2020

  PSC is a vaccine company with a novel cell-based technology designed to produce multiple vaccine candidates in unprecedented speed. PSC is a vaccine company with a novel cell-based technology designed to produce multiple vaccine candidates in unprecedented speed.



Merck Research Laboratories

• Executive Director, Clinical Research

  • 2009 - Jan 2011



Schering-Plough Research Institute

• United States
• Pharmaceutical Manufacturing
• 400 - 500 Employee

• Executive Director, Global Clinical Research

  • 2004 - 2009

  Headed team developing CCR5 antagonist vicriviroc for treatment of HIV Headed team developing CCR5 antagonist vicriviroc for treatment of HIV



Achillion Pharmaceuticals

• Senior Vice President, Drug Development

  • 2000 - 2003

  Built Drug Develpment team; headed development of lead compound from Pharmaceutical Development through Phase 2 for treatment of HIV and HBV. Built Drug Develpment team; headed development of lead compound from Pharmaceutical Development through Phase 2 for treatment of HIV and HBV.



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Executive Director, Antiviral Clinical Research

  • 1989 - 2000

  Headed team that designed and conducted Phase 2-4 clinical trials of antiviral agents directed at HIV, HBV, HCV and CMV. Maintained contact and a positive relationship with HIV community advocates.. Headed team that designed and conducted Phase 2-4 clinical trials of antiviral agents directed at HIV, HBV, HCV and CMV. Maintained contact and a positive relationship with HIV community advocates..



St. Louis University School of Medicine

• Professor of Pediatrics and Microbiology

  • Jul 1976 - Jun 1989

  Chief of Infectious Diseases and Hospital Epidemiology at Cardinal Glennon Hospital for Children Chief of Infectious Diseases and Hospital Epidemiology at Cardinal Glennon Hospital for Children